Hong Kong Equities See Reshuffling Amid Buybacks and Asset SalesGlobal Report·Jul 28 at 04:12 AM01873+3.17%02656+4.66%
VIVA Biotech files HKEX next-day disclosure return, reports share repurchase for cancellationPUBT·Jun 26 at 06:22 AM01873+3.17%
VIVA Biotech shareholders adopt 2025 audited financial statements at AGMPUBT·Jun 26 at 03:31 AM01873+3.17%
Viva Biotech grants 6.22 million RSUs to CDMO staff at HK$ 1.08 eachPUBT·Jun 26 at 02:23 AM01873+3.17%
KE Holdings files HKEX next-day return disclosing share repurchase for cancellationPUBT·Jun 24 at 06:37 AMBEKE-0.24%02423+5.00%
Viva Biotech files HKEX next-day disclosure return announcing share repurchase for cancellation at HKD 1.12 eachPUBT·Jun 24 at 05:06 AM01873+3.17%
From Hit Identification to Lead Optimization: Building Scientific Continuity in Early Drug DiscoveryPR Newswire·May 27 at 09:37 PM01873+3.17%FBT-3.01%
05:19 ETFifteen Years Alongside Europe's Drug Discovery Teams: Viva Biotech Strengthens Continuity from Discovery to Development and Manufacturingprnewswire·Apr 7 at 04:20 AM01873+3.17%FBT-3.01%
10:01 ETViva Biotech Announces 2025 Annual Results: AI-Driven Drug Discovery Reinforces Industry Leadership, CDMO Commercial Products Enter Rapid Scale-Upprnewswire·Mar 30 at 09:03 AM01873+3.17%FBT-3.01%
"Performance" VIVA BIOTECH's annual net profit is 220 million RMB, an increase of 31.4%, no dividend declaredAASTOCKS·Mar 30 at 08:41 AM01873+3.17%159837+1.04%
Viva Biotech Profits Rise in 2025 Despite Revenue DeclineTip Ranks·Mar 30 at 07:55 AM159837+1.04%159849+0.61%
21:00 ETViva Biotech Accelerates AI-Driven Drug Discovery and Advance the 'Lab-in-the-Loop' with NVIDIAprnewswire·Mar 16 at 08:00 PMIBBQ-1.83%ZIVO0.00%
